Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
14
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-13 Eisai Co.,Ltd. “Clinical data supporting the efficacy and safety of the "Rekenbi®" subcutaneous autoinjector, comparable to intravenous formulations, in early Alzheimer's disease were presented at AAIC 2026. New clinical and real-world data support a subcutaneous treatment pathway from initial therapy to ongoing therapy, contributing to improved convenience for patients and care partners.”
14
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-13 Shionogi & Co.,Ltd. “Regarding the signing of a joint research agreement with Nagasaki University and MMV aimed at creating new malaria preventive drugs, and the selection of the project by the GHIT Fund.”
14
Jul
Astellas Pharma Inc. JP3942400007
2026-07-13 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in the United States as neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer, regardless of whether cisplatin is indicated, in combination with pembrolizumab.”
11
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-10 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory expands manufacturing capacity for intravenous fluid products in North America to improve supply stability and promote the availability of DEHP-free intravenous fluid containers.”
11
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-10 Otsuka Holdings Co.,Ltd. “Otsuka Holdings publishes its "Integrated Report 2026".”
07
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-06 Otsuka Holdings Co.,Ltd. “Astex, a UK subsidiary, has announced an exclusive research partnership and licensing agreement with Genentech for its breast cancer treatment project.”
04
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-03 Shionogi & Co.,Ltd. “We have posted the video and transcript of the 161st Ordinary General Meeting of Shareholders.”
01
Jul
Eisai Co.,Ltd. JP3160400002
2026-06-30 Eisai Co.,Ltd. “UCL and Eisai extend joint research agreement to accelerate the creation of treatments for neurodegenerative diseases.”
01
Jul
Eisai Co.,Ltd. JP3160400002
2026-06-30 Eisai Co.,Ltd. “At the Alzheimer's Disease Association International Conference 2026 (AAIC2026), the Alzheimer's disease portfolio was presented through more than 50 presentations.”
01
Jul
Eisai Co.,Ltd. JP3160400002
2026-06-30 Eisai Co.,Ltd. “Eisai Co., Ltd.: Personnel changes and organizational restructuring.”
01
Jul
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-06-30 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Enspring (application for thyroid eye disease accepted by the U.S. FDA).”
01
Jul
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-06-30 CHUGAI PHARMACEUTICAL CO.,LTD. “We have begun collaborative research using real-world data and generative AI (LLM) to improve the accuracy and efficiency of selecting potential clinical trial patients.”
30
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-29 Otsuka Holdings Co.,Ltd. “We have established a joint research program with Tohoku University, "Joint Research Course on Water Metabolism and Total Conditioning," aiming to establish a scientific foundation for individualized water management and acquire knowledge that contributes to maintaining health.”
30
Jun
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of datopotamab deruxtecan (Dato-DXd/DS-1062) as a first-line treatment for triple-negative breast cancer (248.5KB) will open in a new window as a PDF file.”
30
Jun
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for Enhertu® (trastuzumab deruxtecan) for Multiple HER2-Positive Solid Tumors in the EU (261.9KB) PDF file will open in a new window.”
26
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-25 Otsuka Holdings Co.,Ltd. “We received our first silver medal in EcoVadis' sustainability assessment.”
26
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-25 Otsuka Holdings Co.,Ltd. “Centanafadine, a novel attention-deficit/hyperactivity disorder (ADHD) treatment with a new mechanism of action: Positive results from a Phase 3b trial in adult ADHD patients with concomitant anxiety disorders.”
25
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-24 Otsuka Holdings Co.,Ltd. “Otsuka America launches "Pocari Sweat Science Advisory Board" and announces new heatstroke prevention guidelines in the United States to address the heat.”
25
Jun
Shionogi & Co.,Ltd. JP3347200002
2026-06-24 Shionogi & Co.,Ltd. “Regarding the disposal of treasury stock as restricted stock compensation.”
25
Jun
Shionogi & Co.,Ltd. JP3347200002
2026-06-24 Shionogi & Co.,Ltd. “We have updated the materials regarding measures to implement management that takes into account the cost of capital and stock prices.”